Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Blossom Wealth Management

Blossom Wealth Management raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.8% during the third quarter, HoldingsChannel.com reports. The firm owned 1,516 shares of the medical instruments supplier’s stock after buying an additional 56 shares during the period. Blossom Wealth Management’s holdings in Becton, Dickinson and Company were worth $366,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $26,000. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Abound Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC lifted its position in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Down 0.4 %

NYSE BDX opened at $239.66 on Wednesday. The business has a fifty day moving average price of $237.20 and a 200 day moving average price of $235.12. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company has a market cap of $69.26 billion, a P/E ratio of 52.79, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the previous year, the business posted $2.96 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. Research analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.